Elpamotide
DRACPC ID DRACPC0049
Active Ingredients Elpamotide
Description A peptide vaccine containing an HLA-A*2402-restricted epitope of vascular endothelial growth factor receptor (VEGFR) 2 with potential immunostimulatory and antineoplastic activities. Upon administration, VEGFR2-169 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against VEGFR2-expressing tumor cells. VEGFR2, a receptor tyrosine kinase, is overexpressed by a variety of tumor types; overexpression is associated with tumor cell proliferation and tumor angiogenesis. HLA-A*2402 is an MHC class I molecule that presents antigenic peptides to CD8+ T cells; epitope design restricted to epitopes that bind most efficiently to HLA-A*2402 may improve antigenic peptide immunogenicity.
Synonyms VEGFR2-169; VEGFR2-169 Peptide Vaccine; L-Arginyl-L-phenylalanyl-L-valyl-L-prolyl-L-alpha-aspartylglycyl-L-asparaginyl-L-arginyl-L-isoleucine Human Soluble (Vascular Endothelial Growth Factor Receptor) VEGFR2-(169-177)-peptide; Elpamotide
Type Biotech
Disease Pancreatic Cancer
Classification
Peptide and derivative Vaccine
Structure Information
Molecular Formula C47H76N16O13
Molecular Weight 1073.2
Active Sequence RFVPDGNRI
Sequence Length 9
Modification None
IUPAC Name (2S,3S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-carboxypropanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpentanoic acid
InChI InChI=1S/C47H76N16O13/c1-5-25(4)37(45(75)76)62-40(70)28(15-10-18-55-47(52)53)58-41(71)30(21-33(49)64)57-34(65)23-56-39(69)31(22-35(66)67)60-43(73)32-16-11-19-63(32)44(74)36(24(2)3)61-42(72)29(20-26-12-7-6-8-13-26)59-38(68)27(48)14-9-17-54-46(50)51/h6-8,12-13,24-25,27-32,36-37H,5,9-11,14-23,48H2,1-4H3,(H2,49,64)(H,56,69)(H,57,65)(H,58,71)(H,59,68)(H,60,73)(H,61,72)(H,62,70)(H,66,67)(H,75,76)(H4,50,51,54)(H4,52,53,55)/t25-,27-,28-,29-,30-,31-,32-,36-,37-/m0/s1
InChI_Key ZAJHBCDPAUKEPU-GIKXZWSFSA-N
SMILES CC[C@H](C)[C@H](NC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@H]1N(C([C@@H](NC([C@@H](NC([C@@H](N)CCC/N=C(N)\N)=O)CC2=CC=CC=C2)=O)C(C)C)=O)CCC1)=O)CC(O)=O)=O)=O)CC(N)=O)=O)CCC/N=C(N)\N)=O)C(O)=O
External Codes
PubChem CID 25210976
DrugBank Accession Number DB16152
NCI Thesaurus Code C74090
UNII S68632MB2G GSRS
CAS 673478-49-4
Drug approval
Drug indication
Investigated for use/treatment in pancreatic cancer.
The drug is not approved.
| ClinicalTrials.gov Identifier | Title | Condition or disease | Phase | Purpose |
|---|---|---|---|---|
| NCT00622622 | Phase I Study of Gemcitabine With Antiangiogenic Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 Derived From VEGFR2 in Patients With Unresectable, Locally Advanced, Recurrent or Metastatic Pancreatic Cancer | Pancreatic Cancer | Phase 1 | Treatment |
| NCT00639925 | Phase I Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer | Pancreatic Cancer | Phase 1 | Treatment |
| NCT00655785 | Phase I/II Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer | Pancreatic Cancer | Phase 1/2 | Treatment |
More clinical information is obtained from ClinicalTrials.gov.
